| Unlike small molecule drugs, biologically derived products are large, complex molecules, requiring a battery of analytical techniques, chemical and instrumental for their structural analysis. Biosimilar molecules face comparable challenges in their characterization. Interested in learning more?
Download the white paper Biosimilar Development: From Science to Market, which provides a comprehensive overview of the regulatory hurdles and characterization challenges of developing a Biosimilar product.
Register to attend the webinar: Biosimilars: Structural Characterization and Comparability Approaches, which describes how to approach biosimilar characterization and comparability to originator molecules. |
SGS SA